Understand the source comparison
Tolerance to SS-LUP-332 Cycling: Research Protocol Comparison
Continuous Daily 10mg once daily, 7 days/week 38% of baseline activation Tolerance develops by week 5–6; requires dose escalation or protocol termination Not recommended—efficacy loss negates consistency benefits 5-Days-On/2-Days-Off 10mg once daily, weekends
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Continuous Daily
- 10mg once daily, 7 days/week
- 38% of baseline activation
- Tolerance develops by week 5–6; requires dose escalation or protocol termination
- Not recommended—efficacy loss negates consistency benefits
- 5-Days-On/2-Days-Off
- 10mg once daily, weekends off
- 71% of baseline activation
- Requires strict adherence; metabolic markers may fluctuate slightly on off-days
- Gold standard for extended research blocks (8–12 weeks)
- 4-Weeks-On/2-Weeks-Off
- 10mg once daily, 4 weeks active + 2 weeks washout
- 82% of baseline activation
- Longer washout disrupts continuity; less practical for time-sensitive studies
- Best for receptor recovery but sacrifices research momentum
- Every-Other-Day
- 10mg on alternate days
- 65% of baseline activation
- Lower peak effects; suitable for maintenance phases, not initial research
- Extends usable duration but produces less dramatic shifts
- Twice-Daily Split Dose
- 5mg twice daily, 7 days/week
- 29% of baseline activation
- Fastest tolerance development; no recovery window between doses
- Avoid—accelerates desensitization without offsetting benefits